Polycyclic Aromatic Hydrocarbon-DNA Adducts in Prostate Cancer
Open Access
- 15 December 2004
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (24) , 8854-8859
- https://doi.org/10.1158/0008-5472.can-04-2323
Abstract
The formation of DNA adducts can lead to DNA replication errors and the potential for carcinogenesis. DNA adducts have been detected in prostate cells, but the distribution of adducts with respect to prostate cancer risk factors and histology is unknown. In a study of 130 Caucasian (n = 61) and African-American (n = 69) men with prostate cancer who underwent radical prostatectomy, we quantified polycyclic aromatic hydrocarbon (PAH)-DNA adducts in prostate tumor and adjacent nontumor cells by immunohistochemistry. A strong correlation between paired adduct levels in the two cell types was observed (r = 0.56; P < 0.0001); however, nontumor cells had a significantly higher level of adducts compared with tumor (0.30 absorbance units ± 0.05 versus 0.17 absorbance units ± 0.04; P < 0.0001). Variables significantly associated with PAH-DNA adduct levels in tumor cells included primary Gleason grade, tumor volume, and log-transformed prostate-specific antigen (PSA) at time of diagnosis. Tumors with a primary Gleason grade of 5 had significantly lower PAH-DNA adduct levels than tumor cells with a primary Gleason grade of 3 or 4 (P < 0.0001 for both). Tumors that involved 10% or less of the prostate gland had significantly higher PAH-DNA adduct levels than tumors that involved 15 to 20% of the prostate gland (P = 0.004). PSA levels were inversely associated with PAH-DNA adduct levels in tumor cells (P = 0.009). A similar, albeit less significant, inverse association was observed between PSA and PAH-DNA adduct levels in nontumor cells (P = 0.07). Interestingly, increasing primary Gleason grade was associated with increasing PAH-DNA adduct levels in adjacent nontumor cells (P = 0.008). Our results show that PAH-DNA adducts are present in the prostate but vary with regard to cellular histology. In prostate tumor cells, decreased cellular differentiation and increased tumor proliferation may reduce PAH-DNA adduct levels.Keywords
This publication has 33 references indexed in Scilit:
- OXIDATIVE DNA DAMAGE IN PATIENTS WITH PROSTATE CANCER AND ITS RESPONSE TO TREATMENTJournal of Urology, 2004
- Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cellsJournal of Cellular Biochemistry, 2004
- Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissueCarcinogenesis: Integrative Cancer Research, 2000
- Human DNA adduct measurements: state of the art.Environmental Health Perspectives, 1996
- Cancer risk due to occupational exposure to polycyclic aromatic hydrocarbonsAmerican Journal of Industrial Medicine, 1995
- Mortality and incidence of cancer in a cohort of Swedish chimney sweeps: an extended follow up study.Occupational and Environmental Medicine, 1993
- The role of aromatic hydrocarbons in the genesis of breast cancerMedical Hypotheses, 1992
- Binding of benzo[a]pyrene to DNA by cytochrome P 450 catalyzed one-electron oxidation in rat liver microsomes and nucleiBiochemistry, 1990
- 32P-postlabeling assay for carcinogen-DNA adducts: nuclease P1-mediated enhancement of its sensitivity and applications.Environmental Health Perspectives, 1987
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986